KNSA

Kiniksa Pharmaceuticals Internat…

• Seeking Alpha·10/02 09:52

  Kiniksa Pharmaceuticals Has Strong Growth And Little Room For Disappointment

• TipRanks·09/30 09:40

  Analysts’ Top Healthcare Picks: Kiniksa Pharmaceuticals (KNSA), Dexcom (DXCM)

• Simply Wall St·09/23 13:44

  Is Kiniksa Pharmaceuticals International (KNSA) A Bargain Or Fully Priced On ARCALYST Growth?

• NASDAQ·09/17 16:13

  Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

• Simply Wall St·09/12 07:24

  Kiniksa Pharmaceuticals International (KNSA) Beat Sales Expectations, Is It Still 22% Undervalued?

• TipRanks·08/13 12:50

  Analysts Are Bullish on Top Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), REPRO-MED Systems (KRMD)

• Simply Wall St·08/09 08:34

  Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)?

• Simply Wall St·08/01 16:28

  Kiniksa Pharmaceuticals International (KNSA) After Raised 2026 Guidance And Strong Q2 Results Looks Fully Valued

• TipRanks·08/01 02:02

  Insider Shake-Up at Kiniksa Pharmaceuticals Sparks Investor Buzz

• Simply Wall St·07/30 20:18

  Kiniksa Pharmaceuticals (KNSA) Stock Cools As Raised Guidance Meets ARCALYST Reliance

• Dow Jones·07/30 18:53

  Kiniksa Pharmaceuticals Price Target Raised to $90.00/Share From $75.00 by Goldman Sachs

• Dow Jones·07/30 18:53

  Kiniksa Pharmaceuticals Is Maintained at Buy by Goldman Sachs

• Benzinga·07/30 18:42

  Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

• NASDAQ·07/30 16:20

  Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

• TipRanks·07/30 06:00

  Lack of Disclosure on Unregistered Equity Sales Clouds Dilution Risks at Kiniksa Pharmaceuticals